Rapid Therapeutic Science Laboratories EBIT

Rapid Therapeutic Science Laboratories (RTSL) currently reports a EBIT of $-100K as of December 2024. That compares with $-1.9M in the prior-year period — up 94.7% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Rapid Therapeutic Science Laboratories's EBIT history and peer comparisons.

Rapid Therapeutic Science Laboratories's EBIT increased from $-1.9M to $-100K — a 94.7% year-over-year increase (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Rapid Therapeutic Science Laboratories's EBIT of $-100K is lower than the its sector sector average of $2.6T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Rapid Therapeutic Science Laboratories reported $-100K in EBIT as of December 2024. That compares with $-1.9M in the prior-year period — up 94.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-100K, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Rapid Therapeutic Science Laboratories, and consider following RTSL for alerts when major investors trade the stock.